Anti-HIV-1 activity and structure-activity relationship of cepharanoline derivatives in chronically infected cells

被引:26
作者
Baba, M [1 ]
Okamoto, M
Kashiwaba, N
Ono, M
机构
[1] Kagoshima Univ, Fac Med, Div Human Retroviruses, Ctr Chron Viral Dis, Kagoshima 890, Japan
[2] Kaken Shoyaku Co, Res Labs, Tokyo, Japan
关键词
cepharanthine; alkaloid; HIV-1; structure-activity relationship; chronic infection; U1cells;
D O I
10.1177/095632020101200506
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cepharanthine (12-O-methyl cepharanoline) is a plant alkaloid and has been shown to inhibit tumour necrosis factor-alpha- or phorbol 12-myristate 13-acetate-induced HIV-1 replication in the chronically infected promonocytic cell line, U1. Its mechanism of action is considered to be the inhibition of nuclear factor kappaB, a potent inducer of HIV-1 gene expression. In this study, we have synthesized 96 derivatives of cepharanoline, including cepharanthine, and examined their inhibitory effects on HIV-1 replication in U1 cells. Among the 12-O-alkyl derivatives, cepharanthine proved to be the most active, and the activity decreased as the length of the alkyl chain increased. All of the 12-O-acyl derivatives were totally inactive, while a few 12-O-carbamoyl derivatives displayed modest activity. Since 12-O-ethyl derivatives were found to be as active as cepharanthine against HIV-1 replication, we further synthesized various 12-O-ethyl derivatives of cepharanoline. Among the derivatives, five proved to be more active inhibitors than cepharanthine, and the most active compound was 12-O-ethylpiperazinyl cepharanoline. The 50% effective concentrations of this compound and cepharanthine were 0.0041 and 0.028 mug/ml (0.0060 and 0.046 muM), respectively.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 20 条
[1]  
Baba M, 2001, ANTIRETROVIRAL THERAPY, P191
[2]   Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives [J].
Baba, M ;
Okamoto, M ;
Makino, M ;
Kimura, Y ;
Ikeuchi, T ;
Sakaguchi, T ;
Okamoto, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1250-1255
[3]   Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities [J].
Butera, ST .
ANTIVIRAL RESEARCH, 2000, 48 (03) :143-176
[4]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA EXPRESSION BY 4 CHRONICALLY INFECTED CELL-LINES INDICATES MULTIPLE MECHANISMS OF LATENCY [J].
BUTERA, ST ;
ROBERTS, BD ;
LAM, L ;
HODGE, T ;
FOLKS, TM .
JOURNAL OF VIROLOGY, 1994, 68 (04) :2726-2730
[5]   Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line [J].
Emiliani, S ;
Fischle, W ;
Ott, M ;
Van Lint, C ;
Amella, CA ;
Verdin, E .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1666-1670
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF THE NERVOUS-SYSTEM - PATHOGENETIC MECHANISMS [J].
EPSTEIN, LG ;
GENDELMAN, HE .
ANNALS OF NEUROLOGY, 1993, 33 (05) :429-436
[7]   CYTOKINE-INDUCED EXPRESSION OF HIV-1 IN A CHRONICALLY INFECTED PROMONOCYTE CELL-LINE [J].
FOLKS, TM ;
JUSTEMENT, J ;
KINTER, A ;
DINARELLO, CA ;
FAUCI, AS .
SCIENCE, 1987, 238 (4828) :800-802
[8]   CEPHARANTHINE (BISCOCLAURINE ALKALOID) TREATMENT IN ENDOTOXIC-SHOCK OF SUCKLING RATS [J].
GOTO, M ;
ZELLER, WP ;
HURLEY, RM .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1991, 43 (08) :589-591
[9]   ACTIVATION OF HIV GENE-EXPRESSION DURING MONOCYTE DIFFERENTIATION BY INDUCTION OF NF-KAPPA-B [J].
GRIFFIN, GE ;
LEUNG, K ;
FOLKS, TM ;
KUNKEL, S ;
NABEL, GJ .
NATURE, 1989, 339 (6219) :70-73
[10]  
KONDO Y, 1992, INT J IMMUNOPHARMACO, V14, P1181